• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    ReWalk Robotics Ltd. filed SEC Form 8-K: Leadership Update, Other Events, Submission of Matters to a Vote of Security Holders

    9/19/23 4:30:31 PM ET
    $RWLK
    Industrial Specialties
    Health Care
    Get the next $RWLK alert in real time by email
    false00-00000000001607962NASDAQ00016079622023-09-132023-09-13


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): September 13, 2023
     
    ReWalk Robotics Ltd.

    (Exact name of registrant as specified in its charter)
      
    Israel
    001-36612
    Not applicable
    (State or Other Jurisdiction of Incorporation)
    (Commission File Number)
    (IRS Employer Identification No.)
     
     
     
    3 Hatnufa St., Floor 6, Yokneam Ilit, Israel
     
    2069203
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: +972.4.959.0123
      
    Not applicable
    (Former name or former address, if changed since last report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
      
    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Ordinary Shares, par value NIS 0.25
     
    RWLK
     
    Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
      
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


    Item 5.02          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    (a) Departure of Directors or Certain Officers.

    The information included below under Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

    (e) Compensatory Arrangements of Certain Officers.
      
    Following the approval of the compensation committee (the “Compensation Committee”) and board of directors (the “Board”) of ReWalk Robotics Ltd. (the “Company”), at the Company’s 2023 annual meeting of shareholders held on September 13, 2023 (the “Meeting”), the Company’s shareholders approved: (i) the Company’s restated Compensation Policy for directors and officers (the “Compensation Policy”); (ii) the grant of 200,000 restricted share units (“RSUs”) to Mr. Larry Jasinski, the Company’s Chief Executive Officer (“CEO”); and (iii) an increase in Mr. Jasinski’s base annual compensation.

    Restated Compensation Policy

    As more fully described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on August 9, 2023, as supplemented (the “Proxy Statement”), material modifications included in the restated Compensation Policy include:


    •
    The CEO may approve an amendment to the terms of service or employment (whether fixed or variable) of any executive officer reporting to him or her who is not also a member of the Company’s Board, provided that (i) such amendment is not material, (ii) such amendment is consistent with the provisions of the Compensation Policy, and (iii) the aggregate effect of such amendment during the term of the Compensation Policy does not exceed three (3) months of such executive officer’s salary for the applicable year;

    •
    Subject to the limits set forth in the Compensation Policy, the Company may offer an executive officer a signing bonus, a retention bonus, or a bonus for relocation;

    •
    The Company may grant an executive officer an annual bonus that will be calculated based on the achievement of various goals and targets, and may grant executive officers who report to the CEO an annual bonus that will be calculated taking into consideration the achievement by the respective executive officer of targets and indicators of various types, in whole or in part, and which may be determined solely by the CEO;

    •
    Any portion of any bonus paid to the CEO that is not based on measurable criteria or that is discretionary, together with all other discretionary components of the CEO’s total bonus payments, to the extent there are such components, shall not exceed three months’ base salary;

    •
    As part of the variable compensation component of any executive officer reporting to the CEO, the CEO may approve a bonus that is not based on measurable criteria, which shall not exceed three months base salary; and

    •
    Equity-based awards for executive officers shall vest over a minimum period of three years, provided, however, that the Board may resolve, under certain circumstances, that the vesting period of any equity-based awards shall be shorter than three years.

    In addition, the restated Compensation Policy includes a separate “clawback policy” attached as Annex A thereto, which complies with the requirements of the Nasdaq Stock Market and would require the return of incentive compensation paid to executive officers in the case of certain restatements of the Company’s financial statements under the terms required by Nasdaq.

    The foregoing summary is not complete and is qualified in its entirety by reference to the Compensation Policy, as amended, which is attached as Appendix B to the Proxy Statement and is incorporated herein by reference.

    Grant of RSUs to Mr. Larry Jasinski and Changes to Mr. Jasinski’s Base Annual Compensation

    As more fully described in the Proxy Statement, the 200,000 RSUs granted to Mr. Jasinski will be granted under the Company’s 2014 Incentive Compensation Plan and will vest in four equal annual installments, commencing as of the date of the Meeting. Mr. Jasinski’s base annual compensation will be increased by five and one-half percent (5.5%) from $419,253 to $442,312, effective as of January 1, 2023.



    Item 5.07          Submission of Matters to a Vote of Security Holders.
     
    An aggregate of 30,362,302 ordinary shares, or 50.36% of the Company’s 59,937,017 ordinary shares issued and outstanding as of August 8, 2023, the record date for the Meeting, were present or voted at the Meeting, constituting a quorum. The following proposals were voted upon at the Meeting, with the results of such voting as set forth below; all proposals, except for Proposal No. 1, the reelection of Yohanan Engelhardt as a Class III director, and Proposal 8, approval, on an advisory basis, of the compensation of the Company’s named executive officers, received the requisite level of approval by shareholders. The proposals are described in greater detail in the Proxy Statement.

    Results of the Meeting
     
    Proposal No. 1: To reelect Yohanan Engelhardt as a Class III director of the board of directors of the Company (the “Board”), to serve until the 2026 annual meeting of shareholders and until his successor has been duly elected and qualified, or until his office is vacated in accordance with the Company’s Articles of Association or the Israel Companies Law, 5759-1999.
     
    Nominee
    For
    Against
    Abstain
    Broker Non-Votes
    Yohanan Engelhardt
    5,657,555
    10,593,238
    406,934
    13,704,575

    Proposal No. 2.: To approve (i) a one-time grant of 200,000 RSUs to Larry Jasinski, the Company’s CEO, and (ii) an increase in Mr. Jasinski’s annual salary by five and one-half percent (5.5%), effective January 1, 2023.
     
    For
    Against
    Abstain
    Broker Non-Votes
    4,346,554
    2,421,327
    9,889,846
    13,704,575

    Proposal No. 3: To approve the extension of the term of the Consulting Agreement with Richner Consultants, LLC, a Delaware company owned by Randel E. Richner, a member of the Board.
     
    For
    Against
    Abstain
    Broker Non-Votes
    14,966,985
    1,004,515
    686,227
    13,704,575

    Proposal No. 4: To approve the Company’s restated Compensation Policy for directors and officers.
     
    For
    Against
    Abstain
    Broker Non-Votes
    4,819,032
    1,760,888
    10,077,808
    13,704,575

    Proposal No. 5: To authorize the Board to determine whether to effect a reverse share split of the Company’s outstanding ordinary shares, par value NIS 0.25 each, and if so, to set a ratio within a range of 1-for-2 to 1-for-12, to be effective on a date to be determined by the Board, and to approve conforming amendments to the Company’s Articles of Association to reflect any such reverse share split.
     
    For
    Against
    Abstain
    Broker Non-Votes
    26,454,420
    3,794,752
    113,127
    —



    Proposal No. 6: Subject to the approval of Proposal 5, and if the Board determines to effect a reverse share split pursuant thereto, to approve amendments to the Company’s Articles of Association authorizing an increase in the Company’s authorized share capital.
     
    For
    Against
    Abstain
    Broker Non-Votes
    24,525,820
    4,914,424
    922,055
    —

    Proposal No. 7: To approve the reappointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as the Company’s independent registered public accounting firm for the year ending December 31, 2023 and until the next annual meeting of shareholders, and to authorize the Board, upon recommendation of the audit committee, to fix the remuneration of said independent registered public accounting firm.
     
    For
    Against
    Abstain
    28,619,227
    1,563,077
    179,997

    Proposal No. 8: To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, pursuant to Item 402 of Regulation S-K of the SEC, including the compensation tables and accompanying narrative disclosures.
     
    For
    Against
    Abstain
    Broker Non-Votes
    4,108,344
    11,613,202
    936,181
    13,704,575

    With regard to Proposal No. 8, the Company’s Compensation Committee takes note of the results of the advisory “say-on-pay” proposal and expects to consider these results and feedback received from the Company’s shareholders among the factors considered in connection with setting the compensation of the Company’s named executive officers.

    Item 8.01          Other Events.

    As described in more detail under Item 5.07 of this Current Report on Form 8-K, Proposal No. 1, the reelection of Mr. Yohanan Engelhardt as a Class III director of the Company, was not approved by the Company’s shareholders at the Meeting.  Accordingly, Mr. Engelhardt was not reelected as a director of the Company, and therefore is no longer a director of the Company, effective immediately upon closing of the Meeting. In addition, as previously disclosed, the departures of Messrs. Aryeh (Arik) Dan, Yasushi Ichiki and Wayne B. Weisman from the Board became effective immediately upon closing of the Meeting.

    In light of the aforementioned director departures, the Board currently consists of six (6) directors.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    ReWalk Robotics Ltd.
     
    Dated: September 19, 2023
    By:
    /s/ Michael Lawless
     
    Name:
    Michael Lawless
     
    Title:
    Chief Financial Officer


    Get the next $RWLK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $RWLK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RWLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VA STAND Act introduced in the United States Senate

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today applauded the introduction of a Senate companion bill to H.R. 6373, the VA Spinal Trauma Access to New Devices (STAND) Act. The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester (D-MT), and the Ranking Member of that committee, Senator Jerry Moran (R-KS).

      3/22/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • Lifeward Announces Reverse Share Split

      Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that effective with the open of the market on Friday, March 15, 2024, the Company will complete a 1-for-7 reverse

      3/13/24 11:45:17 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy

      Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy. Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded. Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline. MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, M

      3/8/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    SEC Filings

    See more
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      1/30/24 4:15:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Other Events

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      12/19/23 4:04:05 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ReWalk Robotics Ltd. (0001607962) (Filer)

      10/13/23 4:31:13 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lind Global Fund Ii Lp bought $40,089 worth of Ordinary Shares (54,917 units at $0.73) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/21/23 4:37:18 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp bought $49,516 worth of Ordinary Shares (72,818 units at $0.68) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/16/23 4:37:44 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp sold $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) and bought $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      9/28/23 4:30:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $RWLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lind Global Fund Ii Lp bought $40,089 worth of Ordinary Shares (54,917 units at $0.73) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/21/23 4:37:18 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp bought $49,516 worth of Ordinary Shares (72,818 units at $0.68) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      11/16/23 4:37:44 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • Lind Global Fund Ii Lp sold $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) and bought $3,521,840 worth of Ordinary Shares (5,031,200 units at $0.70) (SEC Form 4)

      4 - ReWalk Robotics Ltd. (0001607962) (Issuer)

      9/28/23 4:30:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • HC Wainwright reiterated coverage on ReWalk Robotics with a new price target

      HC Wainwright reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously

      3/8/21 8:24:25 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • HC Wainwright & Co. reiterated coverage on ReWalk Robotics with a new price target

      HC Wainwright & Co. reiterated coverage of ReWalk Robotics with a rating of Buy and set a new price target of $3.50 from $2.50 previously

      3/1/21 7:05:13 AM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Leadership Updates

    Live Leadership Updates

    See more
    • ReWalk Robotics Appoints Michael Lawless as Chief Financial Officer

      MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Sept. 08, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) (the "Company" or "ReWalk"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced the appointment of Michael Lawless, CPA, as Chief Financial Officer, effective September 19, 2022. Mr. Lawless brings more than 20 years of experience leading finance and investor relations activities at life science and technology companies to drive greater financial discipline, better strategic decision making, and improved access to capital. "Mike brings an extensive background in strategic finance and investor relations

      9/8/22 8:30:34 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Confirms Receipt of Director Candidate Nominations from Creative Value Capital

      Shareholders Are Not Required to Take Action at This Time MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received notice from Creative Value Capital Limited Partnership ("CVC"), which claims to hold approximately 3% of ReWalk's outstanding shares, that it intends to nominate two candidates for election to the Company's Board of Directors (the "Board") and submit two additional proposals for consideration at the 2022 Annual Meeting of Shareholders (the "Annual

      5/19/22 7:55:01 AM ET
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Announces the Appointment of Joseph E. Turk, Jr. to their Board of Directors

      MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, April 20, 2022 (GLOBE NEWSWIRE) -- ReWalk Robotics. Ltd. (NASDAQ:RWLK) ("ReWalk" or "The Company"), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, announced today that the Board has approved the appointment of Joseph Turk, Jr. to the Board of Directors, effective today. After initiating his career at McKinsey and Company, Mr. Turk has assembled an extensive history in the medical device industry beginning with his role as Director of New Business Development at Boston Scientific. Subsequently, he held multiple roles at NxStage Medical, including President, where he led all commercialization

      4/20/22 4:05:07 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by ReWalk Robotics Ltd. (Amendment)

      SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)

      9/28/23 4:30:11 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • SEC Form SC 13D/A filed by ReWalk Robotics Ltd. (Amendment)

      SC 13D/A - ReWalk Robotics Ltd. (0001607962) (Subject)

      3/9/23 4:20:24 PM ET
      $RWLK
      Industrial Specialties
      Health Care
    • SEC Form SC 13D filed by ReWalk Robotics Ltd.

      SC 13D - ReWalk Robotics Ltd. (0001607962) (Subject)

      2/22/23 5:21:58 PM ET
      $RWLK
      Industrial Specialties
      Health Care

    $RWLK
    Financials

    Live finance-specific insights

    See more
    • Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results

      Highest quarterly and annual revenue in the history of LifewardCommercial and operational integration complete; synergiesexpected to yield $3 million in annual net savings MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced its financial results for the three months and full year ended December 31, 2023. Highlights of the Fourth Quarter of 2023 and Early 2024

      2/27/24 8:00:07 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024

      MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company will release its fourth quarter and fiscal year-end 2023 financial results before the markets open on Tuesday, February 27, 2024. Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the f

      2/20/24 8:30:00 AM ET
      $LFWD
      $RWLK
      Industrial Specialties
      Health Care
    • ReWalk Robotics Reports Third Quarter 2023 Financial Results

      Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts to Attain Medicare Payment Coverage of Exoskeletons MARLBOROUGH, Mass., BERLIN and YOKNEAM ILLIT, Israel, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (NASDAQ:RWLK) ("ReWalk" or the "Company"), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced its financial results for the three and nine months ended September 30, 2023. Highlights of the Third Quarter of 2023 include: Closing of ReWalk's acquisition o

      11/14/23 8:06:13 AM ET
      $RWLK
      Industrial Specialties
      Health Care